* BioLife Solutions Inc BLFS.OQ BLFS.O is expected
to show a
rise in quarterly revenue when it reports results on November
9.
* The Bothell Washington-based company is expected to
report a
24.4% increase in revenue to $42.064 million from $33.8 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for BioLife Solutions
Inc is
for a loss of 17 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for BioLife
Solutions
Inc is $31, above its last closing price of $19.18.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.23 -0.21 -0.06 Beat 72
Mar. 31 2022 -0.25 -0.25 -0.17 Beat 31.1
Dec. 31 2021 -0.16 -0.17 -0.37 Missed -119.5
Sep. 30 2021 -0.09 -0.09 0.00 Beat 100
Jun. -0.09 -0.07 -0.12 Missed -80
30 2021
Mar. 31 2021 -0.04 -0.04 -0.03 Beat 21.7
Dec. 31 2020 -0.02 -0.06 Missed -180
Sep. 30 2020 -0.01 -0.02 -0.08 Missed -336.4
This summary was machine generated November 8 at 03:12 GMT. All
figures in US dollars unless otherwise stated